Astal Laboratories Signs LOI with Immuna Therapeutics for Exclusive India Rights to Next-Gen CAR-T Cell Therapies

Astal Laboratories Ltd. has signed a Letter of Intent (LOI) with Switzerland-based Immuna Therapeutics GmbH for the exclusive India rights to next-generation CAR-T cell therapies, including TriCAR-T platforms. The proposed collaboration covers technology transfer, localization of manufacturing, clinical development, and commercialization in India. This initiative aligns with the company's long-term strategy to expand into high-value advanced therapies and cell and gene therapy platforms. Astal estimates the collaboration will generate incremental revenue of approximately INR 300 crore upon implementation, driven by rising demand for advanced oncology treatments and improved access through localized manufacturing. The partnership positions the Company at the forefront of next-generation immuno-oncology in India while creating a scalable platform for future cell therapy programs.